Syntro Health Appointed to Support Stabl-Im Clinical Program

Summary by 6ix AI

TrivarX Limited has announced the engagement of Syntro Health to support the formulation of its Stabl-Im investigational product for clinical trials. This partnership marks a significant milestone in the preparations for the planned clinical feasibility study of Stabl-Im, which aims to evaluate its safety and pharmacokinetics. Syntro Health will provide laboratory formulation activities, leveraging its expertise in pharmaceutical manufacturing to aid in the development of the product. The planned feasibility study is set to begin patient enrollment in the first quarter of the following year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries